Showing results (1461-1470 of 6,719) with videos related to

Sort By:
Pageof 672
Annals of Hematology|January 24, 2024
Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohortYuanyuan Pei, Jihong Zhu, Ranran Yao, et al.
Annals of Hematology|January 17, 2024
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumabMin Qing, Tianyuan Zhou, Tatiana Perova, et al.
Annals of Hematology|December 27, 2023
Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemiaPengli Huang, Henghui Chang, Ruidong Zhang, et al.
Annals of Hematology|January 3, 2024
Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipientsKiyan Heybati, Domenic Ochal, William Hogan, et al.
Annals of Hematology|January 4, 2024
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)Carlos Vallejo, Ana Rosell, Blanca Xicoy, et al.
Annals of Hematology|December 20, 2023
Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myelomaC Riedhammer, J Düll, C Kestler, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Annals of Hematology|December 7, 2023
Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic Leukemia: a single-center analysis of 67 casesTaekeun Park, Ja Min Byun, Dong-Yeop Shin, et al.
Annals of Hematology|March 16, 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective studyNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, et al.
Annals of Hematology|March 4, 2024
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignanciesPatrick Reimann, Verena Petzer, Axel Mündlein, et al.
Pageof 672